PCOS Has A New Name – PMOS: Understanding the New Name for a Common Hormonal Condition

A major update in reproductive healthcare is underway. In May 2026, an international consortium of researchers, clinicians, and patient advocates announced that Polycystic Ovary Syndrome (PCOS) will be renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change was endorsed by the American Society for Reproductive Medicine (ASRM) following a global consensus process involving more than 14,000 patients and healthcare professionals worldwide. Experts concluded that the previous name inaccurately suggested the presence of ovarian cysts and failed to reflect the condition's broader endocrine and metabolic effects.

PMOS affects approximately 1 in 8 women worldwide, making it one of the most common hormonal disorders affecting reproductive-aged women. Yet many patients experience years of delayed diagnosis, confusion about their symptoms, and frustration with the condition's name. The new terminology aims to improve awareness, diagnosis, and long-term care.

Why Was the Name Changed?

For decades, healthcare professionals and patient advocacy groups have argued that the name "Polycystic Ovary Syndrome" was misleading.

The international consensus group behind the change noted that the condition is not defined by ovarian cysts. Instead, PMOS is a complex disorder involving endocrine, metabolic, and ovarian dysfunction. Researchers also found that the previous name contributed to confusion among patients, clinicians, policymakers, and the public.

According to Dr. Heather Huddleston, director of the PCOS Clinic at UCSF Health, the former name often created unnecessary anxiety because many patients assumed the condition involved ovarian cysts that could rupture, cause pain, or require treatment. In an interview with Everyday Health, she explained that the term "cyst" frequently led to misunderstandings about the condition.

Dr. Huddleston also notes that the ovaries of people with PMOS do not typically contain pathological cysts. Instead, they often contain a higher-than-average number of small immature follicles, which are normal ovarian structures. This distinction was one of the driving factors behind the international effort to rename the condition.

More Than an Ovarian Disorder

The new name reflects what researchers have learned over the past several decades: PMOS affects much more than the ovaries.

The condition can impact multiple aspects of health, including:

• Ovulation and menstrual cycles
• Fertility
• Insulin resistance
• Weight regulation
• Blood sugar levels
• Cardiovascular health
• Mental health
• Skin and hair growth

The international consensus panel concluded that the previous name focused too narrowly on ovarian findings and failed to capture the multisystem nature of the condition.

Improving Diagnosis and Awareness

Delayed diagnosis remains a significant challenge for many patients living with PMOS.

Dr. Huddleston has emphasized that many women spend years seeking answers before receiving an accurate diagnosis. She has also observed that uncertainty about diagnostic criteria can contribute to delayed diagnoses and referrals, resulting in patients seeing multiple providers before receiving appropriate care.

These concerns are echoed by international research showing that many individuals with the condition remain undiagnosed. Experts hope the new name will help improve recognition among both patients and healthcare professionals.

PMOS and Fertility

One of the most common concerns for patients with PMOS is fertility.

According to Dr. Huddleston, many women with PMOS ovulate infrequently or not at all. Because ovulation is necessary for pregnancy, irregular or absent ovulation can lead to infrequent menstrual cycles and make conception more difficult.

The good news is that PMOS-related infertility is often highly treatable.

Dr. Huddleston notes that a variety of effective therapies can help patients ovulate and achieve pregnancy. Treatment options may include lifestyle interventions, medications that stimulate ovulation, and assisted reproductive technologies when appropriate.

At the UCSF Center for Reproductive Health, treatment plans are individualized based on each patient's medical history, fertility goals, and overall health.

Understanding the Metabolic Component

One of the most important additions to the new name is the word "metabolic."

Research has shown that insulin resistance plays a central role in PMOS and is present in the majority of affected women. Insulin resistance can contribute to weight gain, make weight loss more challenging, and increase the risk of long-term health conditions such as type 2 diabetes and cardiovascular disease.

Dr. Huddleston has noted that insulin resistance is one of the most common features of the condition and often contributes to many of the symptoms patients experience.

By incorporating "metabolic" into the new name, experts hope to increase awareness of these important health considerations and encourage more comprehensive care.

A Multidisciplinary Approach to Care

Because PMOS affects multiple body systems, effective treatment often requires a multidisciplinary approach.

As Dr. Huddleston has explained, treatment should be tailored to each patient's specific symptoms, concerns, and goals. For some patients, the primary focus may be fertility. For others, managing irregular cycles, metabolic health, weight concerns, or long-term disease prevention may be the priority.

At UCSF, patients may work with reproductive endocrinologists, nutrition specialists, mental health providers, and other healthcare professionals to address the full spectrum of PMOS-related concerns.

What Patients Should Know

Although the name has changed, the condition itself has not.

PMOS refers to the same condition previously known as PCOS, but with terminology that better reflects current scientific understanding. The transition to the new name is expected to occur gradually over the next several years as healthcare systems, researchers, professional organizations, and clinical guidelines adopt the updated terminology.

The goal of the name change is simple: to improve understanding of a common but often misunderstood condition.

By better reflecting the endocrine, metabolic, and ovarian features of the disorder, experts hope the transition from PCOS to PMOS will support earlier diagnosis, more comprehensive treatment, and improved health outcomes for millions of women worldwide.